Thomas  Englese net worth and biography

Thomas Englese Biography and Net Worth

Insider of Elutia
Tom Englese has served as our Chief Commercial Officer since July 2019. Prior to joining Aziyo, Mr. Englese served as General Manager of North America Hospital Therapies for Mallinckrodt Pharmaceuticals, a publicly traded pharmaceutical company, from April 2015 to July 2019, where Mr. Englese was responsible for the overall profit and loss management. Mr. Englese also served as Vice President Customer Operations from October 2008 to March 2015 for Ikaria, Inc., which was acquired by Mallinckrodt Pharmaceuticals in 2015, and was a member of the Business Development and Transaction team. From 2002 to 2008, Mr. Englese served as Senior Director of Business Operations at Baxter, a publicly traded healthcare company. Mr. Englese holds an M.B.A. from Pennsylvania State University and a B.S. in Marketing from Villanova University.

Before joining Ikaria Mr. Englese held numerous roles with Baxter in the Anesthesia and Critical Care division. Mr. Englese holds a Master of Business Administration in Finance from The Pennsylvania State University and a Bachelor of Science in Marketing and Communications from Villanova University.

What is Thomas Englese's net worth?

The estimated net worth of Thomas Englese is at least $56,976.06 as of March 9th, 2023. Mr. Englese owns 17,917 shares of Elutia stock worth more than $56,976 as of March 28th. This net worth evaluation does not reflect any other assets that Mr. Englese may own. Learn More about Thomas Englese's net worth.

How do I contact Thomas Englese?

The corporate mailing address for Mr. Englese and other Elutia executives is 12510 Prosperity Drive, Suite 370, Silver Spring, MD 20904, United States. Elutia can also be reached via phone at 240-247-1170 and via email at [email protected]. Learn More on Thomas Englese's contact information.

Has Thomas Englese been buying or selling shares of Elutia?

Thomas Englese has not been actively trading shares of Elutia during the last quarter. Most recently, Thomas Englese sold 289 shares of the business's stock in a transaction on Thursday, March 9th. The shares were sold at an average price of $4.30, for a transaction totalling $1,242.70. Following the completion of the sale, the insider now directly owns 17,917 shares of the company's stock, valued at $77,043.10. Learn More on Thomas Englese's trading history.

Who are Elutia's active insiders?

Elutia's insider roster includes Thomas Englese (Insider), Matthew Ferguson (CFO), and Ronald Lloyd (CEO). Learn More on Elutia's active insiders.

Thomas Englese Insider Trading History at Elutia

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/9/2023Sell289$4.30$1,242.7017,917View SEC Filing Icon  
12/14/2021Buy4,580$6.10$27,938.00View SEC Filing Icon  
See Full Table

Thomas Englese Buying and Selling Activity at Elutia

This chart shows Thomas Englese's buying and selling at Elutia by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Elutia Company Overview

Elutia logo
Elutia Inc., a commercial-stage company, engages in developing and commercializing drug-eluting biomatrix technology to enhance surgical outcomes. It offers CanGaroo Envelope, which is used for the stabilization of implantable cardiac devices, such as pacemakers and defibrillators. The company also engages in the development of CanGaroo RM for delivery directly to the surgical site. In addition, it offers SimpliDerm Acellular Dermal Matrix used primarily in breast reconstruction following mastectomy. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.
Read More

Today's Range

Now: $3.18
Low: $3.15
High: $3.27

50 Day Range

MA: $3.56
Low: $2.82
High: $4.07

2 Week Range

Now: $3.18
Low: $1.10
High: $4.19

Volume

4,726 shs

Average Volume

24,870 shs

Market Capitalization

$77.18 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.54